share_log

Is Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Stock's Recent Performance A Reflection Of Its Financial Health?

Is Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Stock's Recent Performance A Reflection Of Its Financial Health?

恩华药业(深交所代码:002262)股票最近的表现是否反映了其财务状况?
Simply Wall St ·  2024/11/22 06:18

Jiangsu Nhwa Pharmaceutical's (SZSE:002262) stock up by 5.8% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on Jiangsu Nhwa Pharmaceutical's ROE.

恩华药业(SZSE:002262)的股票在过去三个月上涨了5.8%。 鉴于市场长期看好强劲的财务状况,我们想知道这是否在这种情况下。 在这篇文章中,我们决定关注恩华药业的roe。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

股东权益回报率(ROE)是用于评估公司管理层利用公司资本效率的关键指标。换句话说,它是一个盈利能力比率,用于衡量股东提供的资本的回报率。

How Is ROE Calculated?

净资产收益率怎么计算?

ROE can be calculated by using the formula:

ROE可以通过以下公式计算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股东权益回报率 = 净利润(来自持续运营)÷ 股东权益

So, based on the above formula, the ROE for Jiangsu Nhwa Pharmaceutical is:

因此,根据以上公式,恩华药业的roe为:

16% = CN¥1.2b ÷ CN¥7.1b (Based on the trailing twelve months to September 2024).

16% = CN¥12亿 ÷ CN¥71亿(基于截至2024年9月的过去十二个月的数据)。

The 'return' is the amount earned after tax over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.16 in profit.

'回报'是过去十二个月税后赚取的金额。这意味着每有1元的股东权益,公司就产生了0.16元的利润。

What Is The Relationship Between ROE And Earnings Growth?

What Is The Relationship Between ROE And Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前为止,我们已经了解到ROE衡量的是公司生成利润的效率。根据公司选择再投资或“保留”的利润比例,我们能够评估公司的未来盈利能力。假设其他条件不变,相较于没有相同特征的公司,既有更高股本回报率又有更高利润保留的公司,通常具有更高的增长率。

Jiangsu Nhwa Pharmaceutical's Earnings Growth And 16% ROE

恩华药业的盈利增长及16%的roe

At first glance, Jiangsu Nhwa Pharmaceutical seems to have a decent ROE. Especially when compared to the industry average of 7.7% the company's ROE looks pretty impressive. This probably laid the ground for Jiangsu Nhwa Pharmaceutical's moderate 12% net income growth seen over the past five years.

乍一看,恩华药业似乎拥有相当不错的ROE。特别是与行业平均水平7.7%相比,公司的ROE显得相当引人注目。这可能为恩华药业过去五年12%的净利润适度增长奠定了基础。

As a next step, we compared Jiangsu Nhwa Pharmaceutical's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 9.1%.

作为下一步,我们将恩华药业的净利润增长与行业进行了比较,令人高兴的是,我们发现该公司的增长高于行业平均增长9.1%。

big
SZSE:002262 Past Earnings Growth November 21st 2024
SZSE:002262 过去的盈利增长 2024年11月21日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Jiangsu Nhwa Pharmaceutical is trading on a high P/E or a low P/E, relative to its industry.

对公司的估值基础在很大程度上与其盈利增长相关。投资者应该尽量判断预期的盈利增长或下降是否已经在股价中反映出来。这将帮助他们判断股票的未来是光明还是黯淡。一个预期盈利增长的良好指标是市盈率,它决定了市场愿意为股票支付多少价格,基于其盈利前景。因此,您可能想查看恩华药业的市盈率是高还是低,相对于其行业。

Is Jiangsu Nhwa Pharmaceutical Making Efficient Use Of Its Profits?

恩华药业是否有效利用其利润?

Jiangsu Nhwa Pharmaceutical has a low three-year median payout ratio of 24%, meaning that the company retains the remaining 76% of its profits. This suggests that the management is reinvesting most of the profits to grow the business.

恩华药业的三年中位 payout 比率为 24%,这意味着该公司保留了剩余 76% 的利润。这表明管理层正在将大部分利润再投资于业务增长。

Additionally, Jiangsu Nhwa Pharmaceutical has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 24%. Therefore, the company's future ROE is also not expected to change by much with analysts predicting an ROE of 18%.

此外,恩华药业在至少十年内支付了分红,这意味着公司相当认真地与股东分享利润。我们最新的分析师数据显示,该公司未来三年的分红派息率预计约为 24%。因此,公司的未来 ROE 预计也不会有太大变化,分析师预测 ROE 为 18%。

Summary

总结

In total, we are pretty happy with Jiangsu Nhwa Pharmaceutical's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

总体而言,我们对恩华药业的表现感到非常满意。 具体来说,我们喜欢这家公司将大量利润以高回报率进行再投资。当然,这导致公司在净利润方面出现了显著增长。 尽管如此,最新的分析师预测表明,公司将继续实现净利润的增长。 这些分析师的预期是基于行业的广泛预期,还是基于公司的基本面?请点击这里查看我们对该公司的分析师预测页面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发